- |||||||||| Angiocept (pegdinetanib) / BMS
Journal: Mutational and biophysical robustness in a pre-stabilized monobody. (Pubmed Central) - Sep 1, 2021
In order to mitigate these losses, we grafted the binding loops from Adnectin-anti-VEGFR2 (CT-322) onto the prestabilized FN3Con scaffold to produce a domain that successfully bound with high affinity to the therapeutic target VEGFR2...Further investigations into buffer excipients doubled the presence of monomeric monobody in accelerated stability trials. These data suggest that loop grafting onto a pre-stabilized scaffold is a viable strategy for the development of monobody domains with desirable biophysical characteristics, and is therefore well-suited to applications such as the evolution of multiple paratopes or shelf-stable diagnostics and therapeutics.
- |||||||||| Angiocept (pegdinetanib) / BMS
Trial termination, Combination therapy, Metastases: Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer (clinicaltrials.gov) - Oct 7, 2013
P2, N=255, Terminated,
These data suggest that loop grafting onto a pre-stabilized scaffold is a viable strategy for the development of monobody domains with desirable biophysical characteristics, and is therefore well-suited to applications such as the evolution of multiple paratopes or shelf-stable diagnostics and therapeutics. Active, not recruiting --> Terminated
- |||||||||| Angiocept (pegdinetanib) / BMS
Trial withdrawal, Monotherapy: Japanese Phase 1 Study of BMS-844203 (CT322) (clinicaltrials.gov) - Feb 5, 2012
P1, N=0, Withdrawn,
Initiation date: Feb 2001 --> Jun 2009 Not yet recruiting --> Withdrawn
|
